Tuesday, August 22, 2017 2:13:50 PM
Looks like CLRB $2.00-land this week,
Because the big buyers are squeezing the shorts until it hurts too much, you know where!
Because the big buyers are squeezing the shorts until it hurts too much, you know where!
Recent CLRB News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 12:23:46 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/04/2026 12:21:32 PM
- Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates • GlobeNewswire Inc. • 03/04/2026 12:15:00 PM
- Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 • GlobeNewswire Inc. • 02/25/2026 01:05:00 PM
- Cellectar Biosciences Expands Global Intellectual Property Estate • GlobeNewswire Inc. • 02/17/2026 01:05:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/13/2026 09:44:33 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/10/2026 08:23:12 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/04/2026 09:11:14 PM
- Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference • GlobeNewswire Inc. • 01/09/2026 01:05:00 PM
- Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies • GlobeNewswire Inc. • 12/16/2025 01:05:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/21/2025 09:05:22 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 11/14/2025 03:46:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 12:30:56 PM
- Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/13/2025 12:20:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 12:00:58 PM
- Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025 • GlobeNewswire Inc. • 11/06/2025 01:05:00 PM
- Cellectar Biosciences stock jumps after FDA grants Rare Pediatric Disease Designation • IH Market News • 10/27/2025 02:48:22 PM
- Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma • GlobeNewswire Inc. • 10/27/2025 12:30:00 PM
- Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research • GlobeNewswire Inc. • 10/14/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2025 08:30:38 PM
- Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million • GlobeNewswire Inc. • 10/07/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2025 11:15:48 AM
- Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM) • GlobeNewswire Inc. • 10/06/2025 11:00:00 AM
- Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer • GlobeNewswire Inc. • 09/30/2025 12:30:00 PM
- Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC) • GlobeNewswire Inc. • 09/24/2025 12:30:00 PM
